



General Meeting Presentation

Dr Michael Thurn,
Managing Director & Chief Executive Officer

ASX|NUZ

20 February 2026

ABN 35 094 006 023



Disclaimer

This disclaimer applies to this presentation and the information contained in it (This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company.

The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.



Our Mission

Advancing groundbreaking science to reach a promising new horizon in treatments for people living with ALS and other neurodegenerative diseases.

Demonstrating Meaningful Progress



Executed Global License Agreement with Elanco



NUZ-001 accepted as the Regimen "I" in the HEALEY ALS Platform Trial



Successful manufacture of three registration batches of NUZ-001



Promising exploratory top-line results from Phase 1 and OLE study



Australian Patent granted for NUZ-001 – Expiry 2041



Secured registered trademark protection for NEURIZON®



R&D Tax Incentive Advance & Overseas Finding Approval



Received ~\$6m cash rebate from R&D Tax Incentive for FY2025



Neurizon common shares approved for trading at OTCQB®



Successfully raised \$7.1m through a share placement



Raised \$5.88m through Entitlement Offer to Eligible Shareholders



Established a \$20m strategic con note facility with Obsidian

Funding Strategy

Strong shareholder support reinforces confidence in Neurizon's strategy and long-term vision



Neurizon's funding has been strongly supported by its existing shareholders and has allowed the company to commit to the HEALEY ALS Platform Trial.

The strategy is focused on protecting shareholders' interests through flexible funding and minimising dilution.

Placement & Entitlement Offer¹

- Raised ~A\$7.1 million under the Placement, through issue of New Shares at A\$0.08 per New Share for the HEALEY ALS Platform Trial
- 2-for-5 Entitlement Offer at A\$0.08 per New Share, raising ~A\$5.9 million (before costs) from participation by eligible shareholders through entitlement and oversubscriptions

Research & Development (R&D) Tax Rebate


- Neurizon's Advance and Overseas Finding (AOF) provides a cash rebate for foreign R&D spend
- Cash rebate of at least 43.5% on HEALEY spend
- AOF is binding on Australian Tax Office and AusIndustry - providing an important, non-dilutive source of funds

Convertible Note Facility

- Convertible Note Facility for up to A\$20 million with Obsidian Global GP, LLC
- Initial draw of only A\$5 million
- Committed facility - option but no obligation to use
- Includes trading restrictions to protect shareholder and optionholder interests

¹ The Company reserves the right to issue any new Shares not issued in the Entitlement Offer ("Shortfall Shares") to new investors or existing shareholders within 3 months of close of the Entitlement Offer at a price no less than the offer price of \$0.08 per Share, in accordance with the terms of the Entitlement Offer.

'Regimen-I' HEALEY ALS Platform Trial Expected Key Milestones



Anticipated Trial Execution Updates

First Patient Dosed and Site Activation

Confirmation trial has commenced with initial clinical sites open and recruitment underway.

Enrolment Milestones Achieved

Progress updates on patient recruitment (e.g., 50% enrolled) and confirmation of continued safety oversight (e.g., Data Safety Monitoring Board (DSMB) review).

Completion Milestones

Last Patient In (LPI) and Last Patient Last Visit (LPLV), with timing guidance for topline data release.

Near-Term Milestones Objectives

- ✓HEALEY ALS Platform Trial– **IRB Approval**
- ✓44th **J.P. Morgan Annual Healthcare Conference and other events**
- ✓Australian **R&D Refund** (net of R&D funding)
- ✓**Fierce Biotech Webinar** with HEALEY
 - **Preclinical Updates**
 - **HEALEY Investigator Meeting**
- HEALEY ALS Platform Trial – **First Patient Dosed**
- Commercial Supply Agreement **with Elanco**

- Ethics Approval for **Liquid Formulation PK Study**
 - **Preclinical Updates**
 - **HEALEY Updates**
- **Liquid Formulation PK Study Initiation**
 - **EMA Scientific Advice** meeting
 - **PDMA Regulatory Consultation**
- American Academy of Neurology Meeting, Target ALS, and other major **international conferences and partnering events**


**CY
2026**

Q1

Q2

ONGOING EFFORTS

- ✓ Work to broaden pipeline to other neurodegenerative diseases
- ✓ Partnership expansion opportunities with patient associations
- ✓ Targeted engagement with potential strategic partners



Registered Address:
Suite 2, Level 11, 385 Bourke Street
Melbourne VIC 3000 Australia
+61 (3) 9692 7222
enquiries@neurizon.com

